Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults |
| |
Authors: | Scott Daniel A Komjathy Steven F Hu Branda T Baker Sherryl Supan Lois A Monahan Carol A Gruber William Siber George R Lockhart Stephen P |
| |
Affiliation: | Wyeth Vaccines Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. |
| |
Abstract: | In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|